ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

4-フェニル酪酸

4-Phenylbutyric Acid

HCID 4775
反応を作成
印刷

データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます

基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
1821-12-1
標準SMILES
O=C(O)CCCc1ccccc1
InChIKey
OBKXEAXTFZPCHS-UHFFFAOYSA-N
分子式
C10H12O2
平均分子量
164.2 g/mol
単同位体質量
164.08372962

概要

4-phenylbutyric acid is a monocarboxylic acid the structure of which is that of butyric acid substituted with a phenyl group at C-4. It is a histone deacetylase inhibitor that displays anticancer activity. It inhibits cell proliferation, invasion and migration and induces apoptosis in glioma cells. It also inhibits protein isoprenylation, depletes plasma glutamine, increases production of foetal haemoglobin through transcriptional activation of the gamma-globin gene and affects hPPARgamma activation. It has a role as an antineoplastic agent, a prodrug, an EC 3.5.1.98 (histone deacetylase) inhibitor and an apoptosis inducer. It is functionally related to a butyric acid. It is a conjugate acid of a 4-phenylbutyrate.

名称と識別子

優先名称
4-Phenylbutyric Acid
IUPAC
4-phenylbutanoic acid
現地名
4-フェニル酪酸
英語名
4-Phenylbutyric acid
分子式
C10H12O2
分子量
164.2

名称と別名

4-PHENYLBUTYRIC ACID4-Phenylbutanoic acid1821-12-1Benzenebutanoic acidBenzenebutyric acidPhenylbutyric acidgamma-Phenylbutyric acidomega-Phenylbutanoic acid4-Phenyl-n-butyric acidCHEBI:41500omega-phenylbutyric acidNSC-295
名称をさらに表示
4-フェニル酪酸4-フェニルブタン酸ベンゼン酪酸4-(フェニル)ブタン酸4-(フェニル)酪酸ベンゼンブタン酸4‐フェニル酪酸4-フェニル酪酸, 99%BuphenylPHENYLBUTYRIC-4 ACIDNSC 2954-benzene acidAKOS BBS-000037494-PHENYBUTYTIC ACID
gamma-Phenyl-n-butyric acid7WY7YBI87ENSC295DTXSID2037631RefChem:55852DTXCID0017631217-341-8Phenylbutyrate

データベース識別子

CAS
1821-12-1
PubChem CID
4775
DTXSID
DTXSID2037631
ChEMBL

物性

構造計算による物性補完中

XLogP
2.4
極性表面積
37.3 Ų
水素結合供与体数
1
水素結合受容体数
2
回転可能結合数
4
重原子数
12
形式電荷
0
複雑度
137

実験および物理化学的性質

Chemical Classes · 2 件

Other Classes -> Organic Acids

Industrial compound

DrugsPharmaceuticals -> Listed in ZINC15
LogP · 2 件

2.42

2.32

Solubility18 mg/mL
Boiling Point290.00 °C. @ 760.00 mm Hg
Melting Point47 - 49 °C
Vapor Pressure0.000664 [mmHg]
Physical Description · 2 件

White or off-white powder; [Alfa Aesar MSDS]

Solid

物理化学的性質

融点
49 · 49-51 °C(lit.)
沸点
165 °C10 · 165 °C10 mm Hg(lit.)
比重(密度)
1.0326 · 1.0326 (rough estimate)
屈折率
1.5405 · 1.5405 (estimate)

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Warning

H315 (83.3%): Causes skin irritation [Warning Skin corrosion/irritation]

P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 12 reports by companies from 7 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

危険有害性情報

Regulatory Information · 2 件

Status: Active Update: 15-05-2018 https://echa.europa.eu/registration-dossier/-/registered-dossier/16079

Benzenebutanoic acid: Does not have an individual approval but may be used under an appropriate group standard

Hazards SummaryA skin and strong eye irritant; [Alfa Aesar MSDS] See Butyric acid.
Hazard Classes and CategoriesSkin Irrit. 2 (83.3%)

毒性情報

Hepatotoxicity · 1 件

While the urea cycle disorders are caused by deficiencies of hepatic enzymes responsible for the elimination of nitrogen, patients generally present with hyperammonemia without other features or biochemical evidence of hepatic injury. Thus, serum aminotransferase, alkaline phosphatase and bilirubin levels are generally normal or only mildly elevated. Newborns presenting with hyperammonemia may have hepatomegaly but other, non-urea cycle, liver function is normal as is hepatic histology. Phenylbutyrate can help to lower ammonia levels acutely and manage to keep them in the normal or near normal range, but generally does not affect other liver functions. In open label studies, a small proportion of patients (particularly with ornithine transcarbamylase [OTC] deficiency) have had ALT or AST elevations, but these have generally been attributed to the underlying condition or its complications. Phenylbutyrate has not been linked to instances of clinically apparent liver injury with jaundice.

化学と産業

薬理情報

Protein BindingWhen co-administered with tauroursodeoxycholic acid as a combination product, the _in vitro_ plasma protein binding of phenylbutyric acid is 82%.
Pharmacodynamics · 1 件

Phenylbutyric acid decreases elevated plasma ammonia glutamine levels in patients with urea cycle disorders. It increases waste nitrogen excretion in the form of phenylacetylglutamine. In the intestines, phenylbutyric acid was shown to reduce mucosal inflammation, regulate transepithelial fluid transport, and improve oxidative status. Some studies report antineoplastic properties of phenylbutyric acid, showing that phenylbutyric acid can promote growth arrest and apoptosis of cancer cells. It is suggested that phenylbutyric acid can act as an ammonia scavenger, chemical chaperone, and histone deacetylase inhibitor.

Mechanism of Action · 1 件

Sodium phenylbutyrate is the most commonly used salt used in drug products of phenylbutyric acid. Sodium phenylbutyrate is a pro-drug that rapidly metabolizes to phenylacetate. Phenylacetate is conjugated with phenylacetyl-CoA, which in turn combines with glutamine via acetylation to form phenylacetylglutamine. Phenylacetylglutamine is then excreted by the kidneys, thus providing an alternate mechanism of waste nitrogen excretion to the urea cycle. Phenylacetylglutamine is comparable to urea, as each molecule contains two moles of nitrogen.

Biological Half-LifeFollowing oral administration of a single 5g dose of sodium phenylbutyrate, the elimination half-life of phenylbutyric acid ranged from 0.76 to 0.77 hours.
Metabolism/Metabolites · 1 件

The major sites for metabolism of sodium phenylbutyrate are the liver and kidney. Phenylbutyric acid is rapidly metabolized to phenylacetate via beta-oxidation. Phenylacetate is conjugated with phenylacetyl-CoA, which in turn combines with glutamine via acetylation to form phenylacetylglutamine.

FDA Pharmacological Classification · 5 件

7WY7YBI87E

PHENYLBUTYRIC ACID

Mechanisms of Action [MoA] - Ammonium Ion Binding Activity

関連反応

147 件
反応記録を作成
HRID 23073 の反応式
HRID 23073反応物として
HRID 28311 の反応式
HRID 28311反応物として
HRID 35155 の反応式
HRID 35155生成物として
HRID 45380 の反応式
HRID 45380反応物として
HRID 50443 の反応式
HRID 50443反応物として
HRID 54063 の反応式
HRID 54063反応物として
HRID 87581 の反応式
HRID 87581反応物として
HRID 112106 の反応式
HRID 112106反応物として
前へ1 / 19 ページ

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
CHEMBL1469
ChEBI
CHEBI:41500
UNII
7WY7YBI87E
EC Number
217-341-8
Nikkaji
J101.512E
闪点
230 °F · >230 °F
貯蔵温度
Sealed in dry,Room Temperature
溶解性
5.3 g/リットル · 5.3g/リットル
外見
結晶性粉末
酸解離定数(Pka)
4.76 · 4.76(at 25℃)
色
白色~やや黄色
水溶解度
40 ℃で5.3g/L · 40℃で5.3g/L
BRN
638180 · 638180
InChI
1S/C10H12O2/c11-10(12)8-4-7-9-5-2-1-3-6-9/h1-3,5-6H,4,7-8H2,(H,11,12)
InChIKey
OBKXEAXTFZPCHS-UHFFFAOYSA-N
SMILES
OC(=O)CCCc1ccccc1
LogP
2.42 · 2.420
CAS データベース
1821 · 1821-12-1(CAS DataBase Reference)
NISTの化学物質情報
4 · 4-Phenylbutanoic acid(1821-12-1)
EPAの化学物質情報
4 · 4-Phenylbutyric acid (1821-12-1)

化学的性質

化学的特性4-Phenylbutyric acid is white to slightly yellowish crystalline powder. It is slightly soluble in chloroform and methanol. Its solubility in water is 5.3 g/l (at 40 °C).

安全データ

wgk
3
tsca
TSCA listed
hs_code
29163900
risk_code
36/37/38
hazard_code
Xi
hazard_note
Irritant
safety_code
22-24/25-36-26
ストレージクラス
11 - Combustible Solids

Established Pharmacologic Class [EPC] - Nitrogen Binding Agent

Phenylbutyric acid is a Nitrogen Binding Agent. The mechanism of action of phenylbutyric acid is as an Ammonium Ion Binding Activity.

MeSH Pharmacological ClassificationSubstances that inhibit or prevent the proliferation of NEOPLASMS.
Absorption, Distribution and Excretion · 2 件

Following oral administration of a single 5g dose of sodium phenylbutyrate, the Cmax was 195-218 µg/mL under fasting conditions and the Tmax was one hour. The effect of food on drug absorption is unknown.

Approximately 80–100% of the dose was excreted by the kidneys within 24 hours as the conjugation product, phenylacetylglutamine. For each gram of sodium phenylbutyrate administered, it is estimated that between 0.12–0.15 grams of phenylacetylglutamine nitrogen are produced.

Tissue LocationsPancreas
Cellular LocationsMembrane

用途と製造

General Manufacturing InformationBenzenebutanoic acid: ACTIVE
応用分野 · 1 件

一般的な説明4-Phenylbutyric acid (4-PBA) is a small-molecular-weight fatty acid with a terminal aromatic group, and its sodium salt (sodium 4-phenyl butyrate) has been used for the treatment of urea cycle disorders. This molecule is also used for the treatment of sickle cell diseases and thalassemia owing to its ability to activate β-globin transcription. Moreover, 4-PBA is employed as an orally bioavailable agent for the treatment of spinal muscular atrophy (SMA) and tumors. Neuroprotective Effects of 4-phenylbutyric Acid and Its Derivatives: Possible Therapeutics for Neurodegenerative Diseases

調製方法

製造方法4-phenylbutyric acid is obtained by the reaction of benzene with butyrolactone in the presence of aluminum chloride, followed by neutralization with base.Synthesis of 4-phenylbutyric acid

純化方法Crystallise the acid from pet ether (b 40-60o). [Beilstein 9 IV 1811.]

上流・下流製品情報

上流原料

アセトン四塩化炭素塩化アルミニウム(III)ベンゼン塩酸メタノール水酸化ナトリウム活性炭素γ-ブチロラクトン

下流製品

3-(4-クロロスルホニルフェニル)プロピオン酸メチルエステル4-フェニルブタン酸メチルイミダプリルクロラムブシルαテトラロン4-フェニルブタン酸エチルMETHYL 4-(4-(BIS(2-CHLOROETHYL)AMINO)PHENYL)BUTYRATEγ-フェニルγ-ブチロラクトン4-(P-ヨードフェニル)酪酸4-フェニルブタノイルクロリド7-ニトロテトラリン-1-オン4-フェニルブチルブロミド
補足説明 · 1 件

定義4-Phenylbutyric acid is a monocarboxylic acid the structure of which is that of butyric acid substituted with a phenyl group at C-4. It is a histone deacetylase inhibitor that displays anticancer activity. It inhibits cell proliferation, invasion and migration and induces apopto is in glioma cells. It also inhibits protein isoprenylation, depletes plasma glutamine, increases production of foetal haemoglobin through transcriptional activation of the gamma-globin gene and affects hPPARgamma activation.